Cowen Inc’s Amicus Therapeutics FOLD Stock Holding History

Cowen Inc’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$2K	Sell	22,500 -30,000	-57%	-$381K	﹤0.01%	436
2019 Q1	$43K	Buy	+52,500	New	+$641K	﹤0.01%	277
2018 Q3	–	Sell	-133,700	Closed	-$2.09K	–	554
2018 Q2	$2.09K	Buy	+133,700	New	+$2.02M	0.09%	153
2016 Q2	–	Sell	-31,000	Closed	-$262K	–	243
2016 Q1	$262K	Buy	+31,000	New	+$220K	0.01%	210

Other funds holding FOLD

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Cowen Inc's FOLD Position: Q1 2019 in Review

Cowen Inc sold out of Amicus Therapeutics (FOLD) in Q1 2019, closing a stake of 12,353 shares — an estimated $151K sold.

Cowen Inc first reported a position in FOLD in Q4 2015 and held it in 7 quarters. The position peaked at $2.22M in Q3 2017. 205 funds tracked by Wall St. Rank hold FOLD as of Q1 2019.

Cowen Inc reported no remaining Amicus Therapeutics position as of Q1 2019 after selling out during the quarter.
Cowen Inc sold 12,353 Amicus Therapeutics shares in Q1 2019, an estimated $151K.
Cowen Inc first reported a position in Amicus Therapeutics in Q4 2015 and held it in 7 quarters.
Cowen Inc's Amicus Therapeutics position peaked at $2.22M in Q3 2017.
205 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2019.

Based on Cowen Inc's 13F filing for Q1 2019, filed 14 May 2019.